Ceritinib Has Clinical Activity in Patients with ROS1-Rearranged NSCLC [Research Watch]

Ceritinib has manageable toxicity and achieves whole-body and intracranial responses.

from Cancer via ola Kala on Inoreader http://ift.tt/2qQoX2t
via IFTTT